Form 4: Lyell Immunopharma Director Ramachandra Acquires Shares and Options

Director Sumant Ramachandra reports acquisition of Lyell Immunopharma shares held in trust and stock options.

Summary

• Sumant Ramachandra, a director at Lyell Immunopharma, reported changes in beneficial ownership.
• Ramachandra acquired 200,000 shares of common stock indirectly through a trust.
• He also acquired options to purchase 130,000 shares of common stock at an exercise price of $0.4017.
• The options vest on the earlier of the next annual meeting of stockholders after May 15, 2025, or the first anniversary of May 15, 2025, contingent on continuous service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard SEC filing detailing insider transactions. The director's acquisition could be seen as slightly positive, but it's not a strong indicator.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Lyell Immunopharma, Ramachandra, Director, Beneficial Ownership, Stock Options, Shares